Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research

A Study of Metabolically Armed CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell Non-Hodgkin lymphoma

Trial Details

NCT ID
NCT06716164
Phase
EARLY_PHASE1
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Metabolically Armed CD19 CAR-T cells
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • All subjects or guardians must sign an informed consent form approved by the Ethics Committee in person before commencing any screening process;
  • Age \> 18 years old, ≤ 70 years old, male or female;
  • Diagnosis of relapsed/refractory (R/R) indolent B-cell lymphoma, and/or R/R diffuse large B-cell lymphoma (DLBCL). Refractory diseases are defined …
  • Patients with relapsed or refractory B-cell lymphoma treated with one standard treatment regimen and one salvage regimen treated with rituximab or …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →